Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

S. Perez Ramirez,M. del Monte-Millán,Sara López-Tarruella,N. Martínez Jañez,Ivan Marquez Rodas,F. Lobo Samper,Y. Izarzugaza Perón,C Rubio Terres,D. Rubio-Rodríguez,José A. García-Sáenz,F. Moreno Antón,P. Zamora Auñón,M. Arroyo Yustos,M. A. Lara Alvarez,E. M. Ciruelos Gil,L. Manso Sánchez,M.J. Echarri González,J.A. Guerra Martinez,C. Jara Sánchez,C. Bueno Muiño,S. Garcia Adrian,J. R. Carrión Galindo,Valentín Maganto,M. Martin

Prospective, multicenter study on the economic and clinical impact of gene-expression assays in early-stage breast cancer from a single region: the PREGECAM registry experience

2019

Introduction The aim of this study is to evaluate the cost-effectiveness and impact of gene-expression assays (GEAs) on treatment decisions in a real-world setting of early-stage breast cancer (ESBC) patients.

Keywords:

Gene expression profiling
Pathology
Breast cancer
Medicine
Oncology
Gene expression
Internal medicine
Quality-adjusted life year
General surgery
multicenter study
cost analysis
treatment decision making

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations